TABLE OF CONTENTS
1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 OVERVIEW OF THE ASIA-PACIFIC TRANSFECTION REAGENTS AND EQUIPMENT MARKET 18
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET APPLICATION COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHT 43
4.1 PESTEL 44
4.2 PORTER'S FIVE FORCES MODEL 45
5 INDUSTRY INSIGHTS: 46
6 ASIA-PACIFIC TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS 47
6.1 EUROPEAN UNION REGULATORY SCENARIO 47
6.2 U.S. REGULATORY SCENARIO 48
6.3 JAPAN REGULATORY SCENARIO 48
6.4 CHINA REGULATORY SCENARIO 49
7 MARKET OVERVIEW 51
7.1 DRIVERS 53
7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES 53
7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS 54
7.1.3 GROWING DEMAND FOR CHIMERIC GENES 54
7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH 55
7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS 55
7.2 RESTRAINTS 56
7.2.1 HIGH COST OF TRANSFECTION PRODUCTS 56
7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS 56
7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE 57
7.3 OPPORTUNITIES 57
7.3.1 EXPLORATION OF EMERGING MARKET 57
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 58
7.3.3 SURGING LEVEL OF INVESTMENT 59
7.4 CHALLENGES 59
7.4.1 LONG APPROVAL PROCEDURE 59
7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION 60
7.4.3 LACK OF TRAINED PROFESSIONALS 61
8 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS 62
8.1 OVERVIEW 63
8.2 REAGENTS & KITS 66
8.3 INSTRUMENTS 67
9 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE 69
9.1 OVERVIEW 70
9.2 RESEARCH 73
9.3 PRECLINICAL 73
9.4 CLINICAL PHASES 74
9.5 COMMERCIAL 75
10 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE 77
10.1 OVERVIEW 78
10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT 81
10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT 81
11 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS 83
11.1 OVERVIEW 84
11.2 NON-VIRAL METHODS 87
11.3 VIRAL METHODS 87
12 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE 89
12.1 OVERVIEW 90
12.2 PLASMID DNA 92
12.3 SMALL INTERFERING RNA (SIRNA) 93
12.4 PROTEINS 94
12.5 DNA OLIGONUCLEOTIDES 95
12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS) 96
12.7 OTHERS 96
13 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM 98
13.1 OVERVIEW 99
13.2 MAMMALIAN CELLS 101
13.3 PLANTS 102
13.4 FUNGI 103
13.5 VIRUS 104
13.6 BACTERIA 105
14 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION 106
14.1 OVERVIEW 107
14.2 IN VITRO APPLICATION 109
14.2.1 IN VIVO APPLICATION 111
14.2.2 BIOPRODUCTION 112
14.2.3 OTHERS 112
14.2.4 SYNTHETIC BIOLOGY 113
14.2.5 AGRICULTURE 113
14.2.6 OTHERS 113
15 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER 114
15.1 OVERVIEW 115
15.2 BIOPHARMA 118
15.3 CROS 118
15.4 CMOS/CDMOS 119
15.5 ACADEMIA 120
15.6 HOSPITALS 121
15.7 CLINICAL LABS 122
15.8 OTHERS 123
16 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL 124
16.1 OVERVIEW 125
16.2 DIRECT TENDER 128
16.3 RETAIL SALES 129
16.4 OTHERS 130
17 ASIA-PACIFIC TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION 131
17.1 ASIA PACIFIC 132
17.1.1 CHINA 137
17.1.2 JAPAN 137
17.1.3 INDIA 137
17.1.4 AUSTRALIA 137
17.1.5 SOUTH KOREA 137
17.1.6 SINGAPORE 137
17.1.7 THAILAND 137
17.1.8 MALAYSIA 137
17.1.9 INDONESIA 137
17.1.10 PHILIPPINES 137
17.1.11 REST OF ASIA-PACIFIC 137
18 ASIA-PACIFIC TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE 138
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 138
19 SWOT ANALYSIS 139
20 COMPANY PROFILE 140
20.1 THERMO FISHER SCIENTIFIC INC. 140
20.1.1 COMPANY SNAPSHOT 140
20.1.2 REVENUE ANALYSIS 140
20.1.3 COMPANY SHARE ANALYSIS 141
20.1.4 PRODUCT PORTFOLIO 141
20.1.5 RECENT DEVELOPMENT 142
20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 143
20.2.1 COMPANY SNAPSHOT 143
20.2.2 REVENUE ANALYSIS 143
20.2.3 COMPANY SHARE ANALYSIS 144
20.2.4 PRODUCT PORTFOLIO 144
20.2.5 RECENT DEVELOPMENT 145
20.3 PROMEGA CORPORATION 146
20.3.1 COMPANY SNAPSHOT 146
20.3.2 COMPANY SHARE ANALYSIS 146
20.3.3 PRODUCT PORTFOLIO 147
20.3.4 RECENT DEVELOPMENT 147
20.4 TAKARA BIO INC. 148
20.4.1 COMPANY SNAPSHOT 148
20.4.2 REVENUE ANALYSIS 148
20.4.3 COMPANY SHARE ANALYSIS 149
20.4.4 PRODUCT PORTFOLIO 149
20.4.5 RECENT DEVELOPMENT 149
20.5 BIO-RAD LABORATORIES, INC. 150
20.5.1 COMPANY SNAPSHOT 150
20.5.2 REVENUE ANANLYSIS 150
20.5.3 COMPANY SHARE ANALYSIS 151
20.5.4 PRODUCT PORTFOLIO 151
20.5.5 RECENT DEVELOPMENT 152
20.6 ALTOGEN BIOSYSTEMS 153
20.6.1 COMPANY SNAPSHOT 153
20.6.2 PRODUCT PORTFOLIO 153
20.6.3 RECENT DEVELOPMENT 154
20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM) 155
20.7.1 COMPANY SNAPSHOT 155
20.7.2 PRODUCT PORTFOLIO 155
20.7.3 RECENT DEVELOPMENT 155
20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC) 156
20.8.1 COMPANY SNAPSHOT 156
20.8.2 REVENUE ANALYSIS 156
20.8.3 PRODUCT PORTFOLIO 157
20.8.4 RECENT DEVELOPMENT 157
20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 158
20.9.1 COMPANY SNAPSHOT 158
20.9.2 PRODUCT PORTFOLIO 158
20.9.3 RECENT DEVELOPMENT 158
20.10 CYTIVA 159
20.10.1 COMPANY SNAPSHOT 159
20.10.2 PRODUCT PORTFOLIO 159
20.10.3 RECENT DEVELOPMENT 159
20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 160
20.11.1 COMPANY SNAPSHOT 160
20.11.2 REVENUE ANANLYSIS 160
20.11.3 PRODUCT PORTFOLIO 161
20.11.4 RECENT DEVELOPMENT 161
20.12 GENLANTIS INC. 162
20.12.1 COMPANY SNAPSHOT 162
20.12.2 PRODUCT PORTFOLIO 162
20.12.3 RECENT DEVELOPMENT 162
20.13 GENO TECHNOLOGY INC., USA 163
20.13.1 COMPANY SNAPSHOT 163
20.13.2 PRODUCT PORTFOLIO 163
20.13.3 RECENT DEVELOPMENT 163
20.14 GINKGO BIOWORKS 164
20.14.1 COMPANY SNAPSHOT 164
20.14.2 PRODUCT PORTFOLIO 164
20.14.3 RECENT DEVELOPMENTS 164
20.15 LONZA 165
20.15.1 COMPANY SNAPSHOT 165
20.15.2 REVENUE ANANLYSIS 165
20.15.3 PRODUCT PORTFOLIO 166
20.15.4 RECENT DEVELOPMENT 166
20.16 MAXCYTE, INC. 167
20.16.1 COMPANY SNAPSHOT 167
20.16.2 REVENUE ANALYSIS 167
20.16.3 PRODUCT PORTFOLIO 168
20.16.4 RECENT DEVELOPMENT 168
20.17 MERCK KGAA 169
20.17.1 COMPANY SNAPSHOT 169
20.17.2 REVENUE ANALYSIS 169
20.17.3 PRODUCT PORTFOLIO 170
20.17.4 RECENT DEVELOPMENT 170
20.18 MIRUS BIO LLC. 171
20.18.1 COMPANY SNAPSHOT 171
20.18.2 PRODUCT PORTFOLIO 171
20.18.3 RECENT DEVELOPMENT 171
20.19 ORIGENE TECHNOLOGIES, INC. 173
20.19.1 COMPANY SNAPSHOT 173
20.19.2 PRODUCT PORTFOLIO 173
20.19.3 RECENT DEVELOPMENT 173
20.20 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.) 174
20.20.1 COMPANY SNAPSHOT 174
20.20.2 REVENUE ANALYSIS 174
20.20.3 PRODUCT PORTFOLIO 175
20.20.4 RECENT DEVELOPMENT 175
20.21 POLYPLUS TRANSFECTION 176
20.21.1 COMPANY SNAPSHOT 176
20.21.2 PRODUCT PORTFOLIO 176
20.21.3 RECENT DEVELOPMENT 176
20.22 R&D SYSTEMS, INC. 178
20.22.1 COMPANY SNAPSHOT 178
20.22.2 PRODUCT PORTFOLIO 178
20.22.3 RECENT DEVELOPMENT 178
20.23 SBS GENETECH 179
20.23.1 COMPANY SNAPSHOT 179
20.23.2 PRODUCT PORTFOLIO 179
20.23.3 RECENT DEVELOPMENT 179
20.24 SIGNAGEN LABORATORIES 180
20.24.1 COMPANY SNAPSHOT 180
20.24.2 PRODUCT PORTFOLIO 180
20.24.3 RECENT DEVELOPMENT 180
21 QUESTIONNAIRE 182
22 RELATED REPORTS 187

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.